A clinical trial of a whole-virus H5N1 vaccine derived from cell culture

New England Journal of Medicine

Volumn 358, Issue 24, 2008, Pages 2573-2584

  Ehrlich, Hartmut J ^a   Müller, Markus ^a   Oh, Helen M L ^b   Tambyah, Paul A ^c   Joukhadar, Christian ^a   Montomoli, Emanuele ^d   Fisher, Dale ^c   Berezuk, Greg ^a   Fritsch, Sandor ^a   Löw Baselli, Alexandra ^a   Vartian, Nina ^a   Bobrovsky, Roman ^a   Pavlova, Borislava G ^a   Pöllabauer, Eva Maria ^a   Kistner, Otfried ^a   Barrett, P Noel ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHANGI GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; HEMAGGLUTININ; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CLADISTICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PANDEMIC; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SHIVERING; VERO CELL; VIRUS STRAIN;

EID: 45149129921     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa073121     Document Type: Article

References (23)

1. Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 2002;20:Suppl 5:40-4.
2. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51.
3. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-64.
4. Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001;356:1953-60.
5. Nicholson KG, Tyrrell DAJ, Harrison P, et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979;7:123-36.
6. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: phase 1 randomised controlled trial. Lancet 2006;368:991-7.
7. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005;23:2943-52.
8. Kistner O, Howard K, Spruth M, et al. Cell culture (Vero) derived whole-virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007;25:6028-36.
9. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero)-derived candidate influenza virus vaccine. Vaccine 1998;16:960-8.
10. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-43.
11. Lu BL, Webster RG, Hinshaw VS. Failure to detect hemagglutination- inhibiting antibodies with intact avian influenza virions. Infect Immun 1982;38:530-5.
12. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004;103:91-5.
13. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-7.
14. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin: applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975;52:43-50.
15. Fitting a model that contains a random effect. In: Collett D. Modeling binary data. Boca Raton, FL: Chapman & Hall/CRC Press, 1991:202-12.
16. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007;370:580-9.
17. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London: European Agency for the Evaluation of Medicinal Products, 1997. (Publication no. CPMP/BWP/214/96.)
18. Wood JM, Gaines-Das RE, Taylor J, Charkraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994;12:167-74.
19. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-43.
20. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-5.
21. Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003;362:1959-66.
22. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004;103:163-71.
23. Constant SL, Bottomly K. Induction of TH1 and TH2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322.